This article was originally published on Ash Clinical News Patients with relapsed/refractory multiple myeloma (MM) who were treated with a combination of subcutaneous daratumumab plus pomalidomide-dexamethasone (Pd) had a 37% lower risk of disease progression or death, compared with those who received Pd alone, according to results from the phase III APOLLO trial. Meletios Dimopoulos, MD, from...Continue Reading
PHYSICAL ADDRESS
Floor 7, 90 The Terrace
Wellington Central
New Zealand